M.J. Safont

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)

Enrique Aranda, J.L. Manzano, Fernando Rivera et al. · Annals of Oncology · 2011 · 49 citations · Full text

Medicine, Oncology, Pharmacology +12

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

Javier Sastre, Pilar García‐Alfonso, José María Viéitez et al. · ESMO Open · 2021 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study.

Carlos Fernández-Martos, M.J. Safont, Jaime Feliú et al. · Journal of Clinical Oncology · 2010 · 10 citations

Medicine, Oncology, Radiology +11